- Named Exclusive Distributor of Second
Point-of-Care Antibody Rapid Test
- Participates in White House COVID-19
Supply Chain Task Force
Henry Schein, Inc. (Nasdaq: HSIC) announced today that it will
serve as the exclusive distributor in the United States of a second
point-of-care rapid test kit that can detect antibodies associated
with COVID-19 in as few as 15 minutes.
“Henry Schein is committed to bringing essential products to the
health care professionals who are fighting the pandemic,” said
Stanley M. Bergman, Chairman of the Board and Chief Executive
Officer of Henry Schein. “During this unprecedented crisis, health
care professionals need rapid diagnostic tools and personal
protective equipment (PPE) to protect their safety and the safety
of the population. In conjunction with our suppliers, we are
determined to make these essential products available.”
Working with BD (Becton, Dickinson and Company) (NYSE: BDX), a
leading global medical technology company, and BioMedomics, a
privately held, North Carolina-based clinical diagnostics company,
Henry Schein will make the test kits available to health care
professionals as part of the Company’s broad offering of
point-of-care rapid tests.
The BioMedomics test analyzes blood, serum, or plasma samples
for the presence of Immunoglobulin M (IgM) and Immunoglobulin G
(IgG) antibodies associated with the coronavirus (SARS-CoV-2). The
test is completed in four simple steps. First, blood is collected
through normal blood collection devices, and then a few drops are
transferred to the test cartridge, followed by two to three drops
of a buffer. The results can be read in 15 minutes.
“The BioMedomics serology test has been validated in numerous
hospitals around the world and will be a critical tool to detect
current or past exposure to COVID-19,” said Dave Hickey, President
of Integrated Diagnostic Solutions for BD. “We are proud to work
with Henry Schein, a leader in the point-of-care segment, to get
these tests to health care providers as quickly as possible.”
The agreement with BD and BioMedomics builds on Henry Schein’s
announcement last week of an antibody rapid blood test, known as
Standard Q COVID-19 IgM/IgG Rapid Test, which is also administered
at the point of care and delivers results within 15 minutes from a
pinprick with no instrumentation required.
“The COVID-19 rapid test kits are a part of Henry Schein’s
response to the outbreak. These tests are important because they
are fast and can be deployed where they are needed to help return
our citizens to the workforce,” Mr. Bergman said. “We believe
public health officials can also use these tests to better
understand the spread of the disease.”
The Company is also a participant in the White House’s COVID-19
Supply Chain Task Force, and has worked with the Strategic National
Stockpile to deliver PPE to COVID-19 testing sites.
Henry Schein’s Brad Connett, President, U.S. Medical Group,
participated in a meeting at the White House on March 29 of the
COVID-19 Supply Chain Task Force. As part of that effort, the
Company is working with the Federal Emergency Management Agency
(FEMA) to source and deliver critical supplies quickly.
“Understandably, demand for test kits and PPE is acute, and the
industry’s supply chain, as of today, is challenged to provide the
volumes that customers require,” Mr. Connett said. “We are
prioritizing shipments of these critical products for use by those
health care professionals on the front line of the COVID-19
pandemic.”
At the meeting, Mr. Connett also stressed the importance of
increasing the manufacturing of PPE in the United States to avoid
future shortages.
Henry Schein has a long-standing record of addressing pandemic
preparedness and response. Among other efforts, Henry Schein is in
direct contact with the World Health Organization and other
multilateral and domestic organizations as part of the Company’s
role as the private-sector lead of the Pandemic Supply Chain
Network, a public-private partnership created in 2015 to improve
the efficiency of the supply chain for personal protective
equipment.
To learn more about what Henry Schein is doing to address this
unprecedented situation and the actions the Company is taking to
get more product into the hands of those who need it most – health
care workers – please visit www.henryschein.com/COVID19update.
For customers interested in more information about the antibody
rapid test kits, please contact Henry Schein at (844) 211-0140.
Current guidance from the U.S. Food and Drug Administration
(FDA) recommends that results from antibody testing should not be
used as the sole basis to diagnose or exclude coronavirus
infection. Depending on the clinical scenario, additional testing
may be considered to further evaluate the possibility of SARS-CoV-2
infection. The test has not been reviewed by the FDA but is
permitted for distribution and use under the public health
emergency guidance issued by FDA on March 16, 2020.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for
health care professionals powered by a network of people and
technology. With more than 19,000 Team Schein Members worldwide,
the Company’s network of trusted advisors provides more than 1
million customers globally with more than 300 valued solutions that
improve operational success and clinical outcomes. Our Business,
Clinical, Technology, and Supply Chain solutions help office-based
dental and medical practitioners work more efficiently so they can
provide quality care more effectively. These solutions also support
dental laboratories, government and institutional healthcare
clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated
distribution network, with a selection of more than 120,000 branded
products and Henry Schein private-brand products in stock, as well
as more than 180,000 additional products available as special-order
items.
A FORTUNE 500 Company and a member of the S&P 500® index,
Henry Schein is headquartered in Melville, N.Y., and has operations
or affiliates in 31 countries. The Company’s sales from continuing
operations reached $10.0 billion in 2019, and have grown at a
compound annual rate of approximately 13 percent since Henry Schein
became a public company in 1995.
For more information, visit Henry Schein at www.henryschein.com,
Facebook.com/HenrySchein, and @HenrySchein on Twitter.
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private
Securities Litigation Reform Act of 1995, we provide the following
cautionary remarks regarding important factors that, among others,
could cause future results to differ materially from the
forward-looking statements, expectations and assumptions expressed
or implied herein. All forward-looking statements made by us are
subject to risks and uncertainties and are not guarantees of future
performance. These forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause our
actual results, performance and achievements or industry results to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. These statements are identified by the use of such
terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,”
“estimate,” “forecast,” “project,” “anticipate,” “to be,” “to
make,” “understand or understanding,” or other comparable terms.
Forward looking statements include the number of tests intended to
be made available and the timing for availability, the nature of
the target market, as well as the efficacy or relative efficacy of
the test results given that the test efficacy has not been
independently verified under normal FDA procedures. A full
discussion of our operations and financial condition, status of
litigation matters, including factors that may affect our business
and future prospects, is contained in documents we have filed with
the United States Securities and Exchange Commission, or SEC, and
will be contained in all subsequent periodic filings we make with
the SEC. These documents identify in detail important risk factors
that could cause our actual performance to differ materially from
current expectations.
Risk factors and uncertainties that could cause actual results
to differ materially from current and historical results include,
but are not limited to: effects of a highly competitive and
consolidating market; increased competition by third party online
commerce sites; our dependence on third parties for the manufacture
and supply of our products; our dependence upon sales personnel,
customers, suppliers and manufacturers; our dependence on our
senior management; fluctuations in quarterly earnings; risks from
expansion of customer purchasing power and multi-tiered costing
structures; increases in shipping costs for our products or other
service issues with our third-party shippers; general global
macro-economic conditions; risks associated with currency
fluctuations; risks associated with political and economic
uncertainty; disruptions in financial markets; volatility of the
market price of our common stock; changes in the health care
industry; implementation of health care laws; failure to comply
with regulatory requirements and data privacy laws; risks
associated with our global operations; risks associated with the
Novel Coronavirus Disease 2019 (COVID-19); risk associated with the
United Kingdom’s withdrawal from the European Union; transitional
challenges associated with acquisitions, dispositions and joint
ventures, including the failure to achieve anticipated
synergies/benefits; financial and tax risks associated with
acquisitions, dispositions and joint ventures; litigation risks;
new or unanticipated litigation developments and the status of
litigation matters; the dependence on our continued product
development, technical support and successful marketing in the
technology segment; our dependence on third parties for certain
technologically advanced components; risks from disruption to our
information systems; cyberattacks or other privacy or data security
breaches; certain provisions in our governing documents that may
discourage third-party acquisitions of us; and changes in tax
legislation. The order in which these factors appear should not be
construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that
many of these factors are beyond our ability to control or predict.
Accordingly, any forward-looking statements contained herein should
not be relied upon as a prediction of actual results. We undertake
no duty and have no obligation to update forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200401005283/en/
Investors Steven Paladino Executive Vice President and Chief
Financial Officer steven.paladino@henryschein.com (631) 843-5500
Carolynne Borders Vice President, Investor Relations
carolynne.borders@henryschein.com (631) 390-8105 Media Ann Marie
Gothard Vice President, Corporate Media Relations
annmarie.gothard@henryschein.com (631) 390-8169
Henry Schein (NASDAQ:HSIC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Henry Schein (NASDAQ:HSIC)
Historical Stock Chart
From Sep 2023 to Sep 2024